IL-1β represents the tip of the iceberg; there are several other potential inflammatory mediators that could be directly targeted to halt atherosclerosis progression, such as by directly targeting the inflammasome, IL-1α, IL-6, IL-18, and IL-33, among others. This evidence concerns the gene IL33 and atherosclerosis.